BioCentury
ARTICLE | Company News

Aug. 26 Company Quick Takes: J&J ordered to pay $572M in opioid trial; plus Taltz, CVRx and Crozet

August 26, 2019 9:40 PM UTC

J&J to appeal ruling in Oklahoma suit
Oklahoma Judge Thad Balkman ruled that J&J's "misleading marketing and promotion of opioids" compromised the health and safety of thousands of Oklahomans and fined the pharma $572 million. Oklahoma Attorney General Mike Hunter was seeking $17.8 billion paid over a 30-year period. Johnson & Johnson (NYSE:JNJ) said it would appeal the decision. The case was heard in the Cleveland County District Court.

Taltz’s label expanded to ankylosing spondylitis
Eli Lilly and Co. (NYSE:LLY) said FDA approved an sBLA for Taltz ixekizumab to treat ankylosing spondylitis. The mAb against IL-17A is already approved to treat plaque psoriasis and active psoriatic arthritis (see “Lilly Planning Submissions for Taltz”)...